Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Cerity Partners LLC

Cerity Partners LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 20,534 shares of the biopharmaceutical company’s stock after acquiring an additional 6,676 shares during the period. Cerity Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $11,546,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. PGGM Investments lifted its position in Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after acquiring an additional 51,900 shares during the last quarter. Founders Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after purchasing an additional 538 shares during the last quarter. Generate Investment Management Ltd purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $6,300,000. Osaic Holdings Inc. increased its stake in shares of Regeneron Pharmaceuticals by 55.2% during the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after acquiring an additional 6,073 shares during the period. Finally, Hudson Value Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $398,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Insider Activity at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,431 shares of company stock valued at $5,733,521 over the last ninety days. Corporate insiders own 7.02% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on REGN. Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Guggenheim lifted their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, HSBC started coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 price objective for the company. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $791.05.

Regeneron Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ REGN opened at $796.55 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The stock’s 50-day simple moving average is $738.12 and its 200-day simple moving average is $628.80. The firm has a market cap of $83.72 billion, a price-to-earnings ratio of 19.07, a PEG ratio of 2.16 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same quarter last year, the firm earned $12.46 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.